View white papers from other Pharmaceutical sectors:
1-15 of 118 results
ASEBIO Report 2010
The most salient indicators include the almost 7% rise in the number of biotech R&D personnel employed and the over 5% growth in private R&D expenditure. In addition, companies carrying out biotechnology R&D grew 12%. Other output indicators are also noteworthy, such as the number of patent applications, which virtually doubled (up 85% in the past year). These indicators confirm the efficiency and strength of the national bioindustry sector.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Future-Proofing Cheminformatics Platforms
If your organization is reviewing your chemical information management capabilities, this white paper summarizes current challenges and opportunities and outlines solutions.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Research Offerings for pre-Clinical Drug Discovery
Download our full case study here.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Company Brochure
Download our company brochure here.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Journal of Biomolecular Screening
Fragment-based drug discovery (FBDD) has become a widely accepted tool that is complementary to high-throughput screening (HTS) in developing small-molecule inhibitors of pharmaceutical targets. Because a fragment campaign can only be as successful as the hit matter found, it is critical that the first stage of the process be optimized. Here the authors compare the 3 most commonly used methods for hit discovery in FBDD: high concentration screening (HCS), solution ligandobserved nuclear magnetic resonance (NMR), and surface plasmon resonance (SPR). They selected the commonly used
saturation transfer difference (STD) NMR spectroscopy and the proprietary target immobilized NMR screening (TINS) as representative of the array of possible NMR methods. Using a target typical of FBDD campaigns, the authors find that HCS and TINS are the most sensitive to weak interactions. They also find a good correlation between TINS and STD for tighter binding ligands, but the ability of STD to detect ligands with affinity weaker than 1 mM KD is limited. Similarly, they find that SPR detection is most suited to ligands that bind with KD better than 1 mM. However, the good correlation between SPR and potency in a bioassay makes this a good method for hit validation and characterization studies.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Target Immobilization and NMR Screening of Fragments in Early Drug Discovery
Using localized NMR spectroscopy on immobilized targets provides us with a method to simultaneously assess binding of small molecules to two different samples. This Target Immobilized NMR Screening (TINS) has a number of advantages, not least is the requirement for minimal quantities of non-isotopically labeled protein and the applicability to
insoluble or unstable targets. The technique is sensitive to binding with KD values in the range of 100 nM to 20 mM, while careful selection of the reference protein reduces the number of false positive hits. This combination ensures a maximal number of valid hits from which to select starting points for hit elaboration projects. Hits can be prioritized using
biological assays when appropriate, as well as an array of biophysical techniques. So far a variety of soluble proteins, including kinases, GTPases, viral targets and proteases, as well as a membrane protein, have been successfully screened against our fragment library. Here we illustrate our experiences with a number of examples which emphasize the
usefulness of the method in selecting and prioritizing fragment hits for elaboration towards leads.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Make time for science with the Rocket
Genevac has followed a continuous programme of collaborative research and development in order to become the world leader in laboratory evaporation science and engineering. The culmination of this work is a revolutionary evaporation technology, now incorporated into the Rocket™ Evaporator.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Introducing the miVac Range
Speeding your concentration, improving your drying. Download the full brochure here.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Introducing the HT Series from Genevac
Genevac's HT Series is the world-leader in solvent evaporation technology for life science research. Download the complete brochure here.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
EZ-2: Everything a Modern Evaporator Should Be - and More
The EZ-2 series draws fully on the expertise of Genevac's engineers and the experiences of many scientists in the laboratory. Using advanced evaporation science, it has been designed specifically for solvent removal in life science research, be that concentration, drying or lyophilisation of samples. For more details, download the full brochure here.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Biovian Company Presentation
Download our company presentation here.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
HPLC Analysis of Fluorescently labelled N-Glycans
To enable the detection following separation of N-glycans by HPLC, the glycans are flourescently labelled with aryl amine compounds by reductive amination. The most commonly used flourescent label is 2-aminobenzamide (2AB), although 2-aminobenzoic acid (2-AA) and 2-aminopyride (2AP) are also used. The labelled glycans can then be analysed by a range of HPLC methods.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Rapid, High Capacity Evaporation Solutions for Sophisticated Fractionation Processes
In the quest to find novel flavor ingredients from nature, powerful equipment that can produce and concentrate fractions derived from natural extracts is essential. Conventionally, many steps of fractionation and evaluation are necessary until a compound is obtained at the purity required for structural analysis.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
Automation Without Robotics: Elimination of Sample Transfer Steps to Optimise Yield and Data Quality in the Laboratory
Changing sample vessel format is an area of Discovery research that can cause problems: sample tracking, sample loss and robotic referencing are among the many drawbacks of having to perform a transfer step. Genevac set out to attempt to "automate" the transfer step within their evaporation systems and developed several concept designs.
Drug Research > Drug Discovery & Development > White Papers
Drug Research > Drug Discovery & Development > White Papers
In Drug Discovery & Development
Drug Discovery & Development Intelligence
Biotechnology Solution Brief
Published by Brainloop
Drug Research > Drug Discovery & Development > White Papers
Managing Primary IND Applications with the FDA
Published by Celerion
Drug Research > Drug Discovery & Development > White Papers
Understanding Pasteurisation and Sterilisation Processes
Published by Tecnosoft
Drug Research > Drug Discovery & Development > White Papers
Beyond Markush – Protecting Activity not Chemical Structure
Published by Cresset
Drug Research > Drug Discovery & Development > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Suppliers Directory
Unilabs York Bioanalytical Solutions - Bioanalytical and Biomarker Specialists
Unilabs York Bioanalytical Solutions is a specialist provider of bioanalytical and biomarker analyses to pharmaceutical and biotech companies, supporting development of small and large molecule therapeutics, from discovery through to post-marketing.
Drug Research > Drug Discovery & Development > Suppliers
ChemAxon - Solutions for Cheminformatics
ChemAxon provides software applications and toolkits for life science researchers and IT developers to enable structure visualization and management, property predictions and calculations, virtual synthesis, screening, clustering and drug design. We support all popular operating systems and web browsers and have nodes and interfaces for other integration routes like web services, SharePoint and workflow platforms such as Pipeline Pilot and KNIME.
Drug Research > Drug Discovery & Development > Suppliers
SGS - Life Science Services
SGS Life Science Services, part of SGS group, has 30 years of experience as a global contract service organisation providing integrated solutions from preclinical activities to phase I-IV trials, bioanalytical and quality control testing.
Drug Research > Drug Discovery & Development > Suppliers
Investigator Location Services - Instant Access to Experienced Clinical Investigators
Investigator Location Services, Inc. (ILS), is the largest study broker with instant access to over 20,000 experienced clinical research investigators in the US and Canada in all medical specialties and practice settings. Our site provides a center for all clinical research and clinical trial personnel solutions.
Drug Research > Drug Discovery & Development > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
